一种简单的模型表明，在活性类风湿关节炎患者的当前治疗中添加每天 5 毫克的缓释泼尼松，可以节省可能的成本。
A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis.
机构信息
Department of Epidemiology and Biostatistics, VU University Medical Center, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
出版信息
Rheumatology (Oxford). 2013 Aug;52(8):1435-7. doi: 10.1093/rheumatology/ket145. Epub 2013 Apr 12.
OBJECTIVE
The effects of a 12-week treatment with modified-release prednisone (MR-pred) on the costs of drug treatment of RA were modelled.
METHODS
With the results of a recent randomized trial as source data, we expressed the effect of treatment (MR-pred vs placebo) on the decrease in the proportion of RA patients meeting disease activity thresholds for reimbursement of biologic treatment.
RESULTS
The results showed 11-13% more patients on MR-pred than on placebo dropped below reimbursement thresholds for The Netherlands, Belgium and the UK. Assuming 1 year of biologics cost €15,000 and MR-pred costs €1/day, €396 are saved in each patient delaying biologic treatment by 12 weeks.
CONCLUSION
Despite a considerably higher cost than conventional prednisone, MR-pred is a cost-effective option for RA patients not on glucocorticoids who are eligible for therapy with biologic agents.
目的
对为期 12 周的改良释放泼尼松（MR-pred）治疗对 RA 药物治疗成本的影响进行建模。
方法
以最近一项随机试验的结果作为源数据，我们表示治疗（MR-pred 与安慰剂）对降低达到生物治疗报销阈值的 RA 患者比例的影响。
结果
结果表明，接受 MR-pred 治疗的患者比接受安慰剂治疗的患者中有 11-13%的患者下降到低于荷兰、比利时和英国的报销阈值。假设生物制剂的 1 年费用为€15,000，MR-pred 的每天费用为€1，每延迟生物制剂治疗 12 周可节省每个患者€396。
结论
尽管 MR-pred 的成本明显高于传统的泼尼松，但对于尚未接受糖皮质激素治疗且有资格接受生物制剂治疗的 RA 患者而言，MR-pred 是一种具有成本效益的选择。
Zotero 插件